ly2181308
Nucleic acidexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2008 (NCT00620321)
Timeline
Indications
Mechanism of action
- Survivin mRNAANTISENSE INHIBITOR
Survivin mRNA antisense inhibitor
BIRC5 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2219774 ↗
Also known as
- gataparsen
- gataparsen
- ly2181308
- ly2181308
- ly2181308
- ly2181308
- ly 2181308
- ly-2181308
- ly-2181308
- ly-2181308
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01107444 | Phase 2 | May 1, 2010 | Eli Lilly |
| NCT00415155 | Phase 1/Phase 2 (Phase 2) | Aug 1, 2008 | Eli Lilly |
| NCT00620321 | Phase 2 | Mar 1, 2008 | Eli Lilly |
| NCT00642018 | Phase 2 | Mar 1, 2008 | Eli Lilly |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 4 | 4 | 1 | 2008 |
1 organizations
Page 1 / 1